IVD

Roche is on the “SurePath” for Cervical Cancer Screening with Approval

FDA has given approval for the Roche’s cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests.

FDA Gets Cancer Test on the Fast Track

Personal Genome Diagnostics received a breakthrough device designation from FDA for the PGDx elio plasma resolve liquid biopsy test.

Could DNA Help Doctors Predict Opioid Addiction?

New research out of Bentley University aims to explore the genetic links between human DNA and opioid addiction. The new study could help doctors identify patients susceptible to opioid dependence and choose different treatment methods.

Are We in Store for More M&A in the Liquid Biopsy Space?

M&A activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.

Monitoring is Key in Precipio’s Liquid Biopsy Success

Precipio merged with Transgenomics last year to expand its liquid biopsy prowess.

Gary Cohen, executive vice president of global health for BD

Collaboration Needed to Fight Antimicrobial Resistance

Diagnostics manufacturers and even medical device innovators can play roles, says an expert working to raise awareness.

Bringing AI to Colorectal Cancer Screening

Freenome has initiated a clinical study to help bring an AI-Genomics blood test for colorectal cancer to the U.S. market.

Grail Brings VC Funding to $1.5B with Latest Round

Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.

Top Tips For R&D Managers Looking To Crack The Lateral Flow Market

Industry expert shows how to navigate the Lateral Flow market.

Proposed Guidelines Could Leave Some PTSD Patients in the Dark

A new study shows proposed changes in the International Classification of Diseases (ICD) guidelines could lead to a reduction in the diagnosis of PTSD patients.

GeneSight Weeds Out Ineffective Drug Therapies for Depression

Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.

Orion Sheds Diagnostic Unit for $200M Plus Milestones

Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.

Companion Diagnostics Space Warms Up with Collaboration

Bristol-Myers Squibb has teamed up with Illumina to develop companion diagnostics for oncology immunotherapies.

Qiagen To Unveil 2 Liquid Biopsy Tests at AACR

Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.